Search

Your search keyword '"Masjuan, Jaime"' showing total 381 results

Search Constraints

Start Over You searched for: Author "Masjuan, Jaime" Remove constraint Author: "Masjuan, Jaime"
381 results on '"Masjuan, Jaime"'

Search Results

2. Outcomes of Decompressive Surgery for Patients With Severe Cerebral Venous Thrombosis: DECOMPRESS2 Observational Study

4. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes

5. Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial

7. Neuropathological findings in fatal COVID-19 and their associated neurological clinical manifestations

8. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

9. COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis.

10. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.

11. Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study.

13. Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults.

16. Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial

18. Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study

20. Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis

22. Factors associated with poor anticoagulation control with vitamin K antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study

23. Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN

26. Genetic Architecture of Ischaemic Strokes after COVID-19 Shows Similarities with Large Vessel Strokes

27. Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine

28. Sex differences in cerebral venous sinus thrombosis after adenoviral vaccination against COVID-19

29. Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia in middle-income countries

30. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry

31. Does normal substantia nigra echogenicity make a difference in Parkinson’s disease diagnosis? A real clinical practice follow-up study

33. Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies

34. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs

35. Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational study

36. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

37. Dihydropyrimidinase-Related Protein 2 Is a New Partner in the Binding between 4E-BP2 and eIF4E Related to Neuronal Death after Cerebral Ischemia

38. Genetic Architecture of Ischaemic Strokes after COVID-19 Shows Similarities with Large Vessel Strokes.

39. Sex differences in cerebral venous sinus thrombosis after adenoviral vaccination against COVID-19

40. A second update on mapping the human genetic architecture of COVID-19

41. Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia in middle-income countries

42. Genetic Architecture of Ischaemic Strokes after COVID-19 Shows Similarities with Large Vessel Strokes

43. Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational study

44. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

46. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

47. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

49. Mechanical thrombectomy for basilar artery thrombosis: a comparison of outcomes with anterior circulation occlusions

50. Preclinical Characterization of Antioxidant Quinolyl Nitrone QN23 as a New Candidate for the Treatment of Ischemic Stroke

Catalog

Books, media, physical & digital resources